Does 82570 require prior authorization?

No, 82570 does not require prior authorization (high confidence). Code is covered without prior authorization.

What is the Medicare reimbursement rate for 82570?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Laboratory tests are not covered unless they are ordered by a physician or other qualified health professional. Please check benefit plan descriptions.
For use of late-night salivary cortisol in diagnosing Cushing's syndrome: exclude exogenous glucocorticoid use and perform testing in patients with multiple and progressive features compatible with the syndrome and patients with adrenal incidentaloma (per Endocrine Society guideline text in policy).
No explicit Medicare documentation or billing requirements are specified in the provided text.
If screening tests (e.g., late-night salivary cortisol or urine cortisol) are positive, a confirmatory second test is recommended and patients should be referred to an endocrinologist (per Endocrine Society guideline text in policy).

Use of the CDOT salivary test in settings such as dentist offices, primary care centers and specialized cancer clinics to aid early detection (as suggested by the authors)
The test was validated in former and current smokers and in younger and older participants (study populations in which the model was evaluated)
Late night salivary cortisol for diagnosing Cushing's syndrome.
ICD-10 covered diagnosis for this indication: E24.0 - E24.9 (Cushing's syndrome).
Use of salivary lactate dehydrogenase (SaLDH) as a potential biomarker for screening, early detection, and follow-up of oral potentially malignant disorders (OPMD) and head and neck cancer (HNC).
Use of salivary biomarkers (including SaLDH and other salivary molecular markers) for detection/diagnosis of oral cancer and head & neck cancers (general statement supported by systematic reviews/meta-analyses).

AETNA-CPB-0608 — Salivary Tests

BCBSIL-MED207.154 — Drug Testing in Pain Management and Substance Use Disorder Treatment

BCBSMT-MED207.154 — Drug Testing in Pain Management and Substance Use Disorder Treatment

BCBSNM-MED207.154 — Drug Testing in Pain Management and Substance Use Disorder Treatment

BCBSOK-MED207.154 — Drug Testing in Pain Management and Substance Use Disorder Treatment

Ask Verity about documentation requirements, denial risks, or coverage in your state.